Lessons learned from recent lipid-lowering trials: Why physicians should change clinical practice - 31/08/11
Address correspondence to: Karol E. Watson, MD, PhD, Division of Cardiology, The David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 47-123 CHS, Los Angeles, CA 90095-1679. Phone: (310) 825-5280. Fax: (310) 206-9133.Abstract |
In the past decade there has been an explosion of data on the beneficial role of cholesterol reduction in the prevention and treatment of cardiovascular disease (CVD). While earlier clinical trials focused primarily on patient populations with very high cholesterol levels, more recent studies have also included individuals with somewhat lower, or “average,” cholesterol levels. What is becoming clearer is that many patients with so-called “average” cholesterol levels may benefit from cholesterol reduction therapy to reduce the risk of cardiovascular events. Recent studies, such as the Heart Protection Study, provide further evidence for cholesterol reduction in the prevention and treatment of CVD and offer valuable lessons about cardiovascular risk reduction.
Le texte complet de cet article est disponible en PDF.
Vol 5 - N° S1
P. S11-S17 - 2003 Retour au numéro
Article précédent
- Reducing major vascular events among VA primary care patients: An extraordinary opportunity
- Karl Hammermeister, Hans Gethoffer
- CME test questions Lipids, diabetes and heart disease
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?